Skip to main content

Table 9 (a) Release kinetics of DOE batches TSP-1 to TSP-10, (b) release kinetics of DOE batches TSP-11 to TSP-20

From: Development, optimization and pharmacokinetic evaluation of biphasic extended-release osmotic drug delivery system of trospium chloride for promising application in treatment of overactive bladder

Trials Unit TSP-1 TSP-2 TSP-3 TSP-4 TSP-5 TSP-6 TSP-7 TSP-8 TSP-9 TSP-10
(a)
Zero order K0 5.298 5.277 4.468 5.303 5.730 6.260 4.693 5.489 5.314 5.000
R2 0.921 0.918 0.986 0.987 0.933 0.551 0.996 0.849 0.974 0.984
First order K 0.107 0.107 0.070 0.097 0.122 0.208 0.077 0.122 0.101 0.090
R2 0.984 0.986 0.902 0.924 0.957 0.981 0.931 0.983 0.958 0.966
Korsmeyer Peppas N 0.642 0.640 1.173 0.931 0.720 0.360 1.001 0.580 0.802 0.821
KKP 14.068 14.075 2.774 6.409 12.340 35.520 4.669 17.262 9.142 8.163
R2 0.998 0.996 0.994 0.989 0.976 0.990 0.996 0.971 0.992 0.999
Higuchi KH 20.348 20.272 16.496 19.881 21.860 24.778 17.533 21.229 20.128 18.913
R2 0.979 0.978 0.819 0.885 0.937 0.958 0.874 0.965 0.929 0.930
Hixon–Crowell KHc 0.029 0.029 0.020 0.027 0.033 0.054 0.022 0.033 0.028 0.025
R2 0.991 0.992 0.934 0.959 0.984 0.961 0.960 0.982 0.984 0.987
Trials Unit TSP-11 TSP-12 TSP-13 TSP-14 TSP-15 TSP-16 TSP-17 TSP-18 TSP-19 TSP-20
(b)
Zero order K0 4.832 4.272 5.284 5.096 5.474 4.810 6.259 5.648 5.794 4.969
R2 0.986 0.984 0.916 0.960 0.878 0.988 0.401 0.872 0.936 0.987
First order K 0.080 0.065 0.107 0.096 0.118 0.083 0.237 0.127 0.122 0.084
R2 0.905 0.901 0.986 0.978 0.986 0.950 0.984 0.980 0.934 0.905
Korsmeyer Peppas n 1.074 1.216 0.632 0.735 0.577 0.898 0.304 0.613 0.762 1.055
KKP 3.938 2.356 14.399 10.522 17.307 6.371 41.223 16.245 11.103 4.268
R2 0.988 0.996 0.999 0.996 0.999 0.992 0.988 0.971 0.965 0.988
Higuchi KH 17.943 15.738 20.311 19.414 21.151 18.088 24.960 21.776 22.014 18.468
R2 0.842 0.810 0.982 0.954 0.993 0.900 0.916 0.958 0.913 0.846
Hixon–Crowell KHc 0.023 0.019 0.029 0.027 0.032 0.023 0.061 0.034 0.033 0.024
R2 0.938 0.932 0.992 0.994 0.987 0.974 0.954 0.989 0.966 0.940